{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:48:46Z","timestamp":1789174126802,"version":"build-2803163510"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R020973\/1"],"award-info":[{"award-number":["MR\/R020973\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X005895\/1"],"award-info":[{"award-number":["MR\/X005895\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1082619"],"award-info":[{"award-number":["1082619"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2026490"],"award-info":[{"award-number":["2026490"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.07.014","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:26Z","timestamp":1753225946000},"page":"420-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria"],"prefix":"10.1016","volume":"44","author":[{"given":"Tayla","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Adderley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-3625","authenticated-orcid":false,"given":"Kylie","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8985-9265","authenticated-orcid":false,"given":"Taane G.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-094X","authenticated-orcid":false,"given":"Christian","family":"Doerig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.07.014_bib0001","series-title":"Antimicrobial Resistance [Fact sheet]. World Health Organization","year":"2021"},{"key":"10.1016\/j.jgar.2025.07.014_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.jgar.2025.07.014_bib0003","series-title":"Antimicrobial resistance: tackling a crisis for the health and wealth of nations","author":"O'neill","year":"2014"},{"key":"10.1016\/j.jgar.2025.07.014_bib0004","series-title":"New WHO report highlights progress, but also remaining gaps, in ensuring a robust pipeline of antibiotic treatments to combat antimicrobial resistance (AMR). World Health Organization","year":"2023"},{"key":"10.1016\/j.jgar.2025.07.014_bib0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.07.014_bib0006","series-title":"HIV and AIDS [Fact sheet]. World Health Organization","year":"2023"},{"key":"10.1016\/j.jgar.2025.07.014_bib0007","unstructured":"World Health Organization. Global Tuberculosis Report 2022. World Health Organization; 2022; World Health Organization. World Malaria Report 2022. World Health Organization; 2022."},{"key":"10.1016\/j.jgar.2025.07.014_bib0008","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41573-024-00933-4","article-title":"Combating antimicrobial resistance in malaria, HIV and tuberculosis","volume":"23","author":"Duffey","year":"2024","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jgar.2025.07.014_bib0009","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D'Costa","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jgar.2025.07.014_bib0010","series-title":"World Health Organization. Global action plan on antimicrobial resistance. World Health Organization","year":"2015"},{"key":"10.1016\/j.jgar.2025.07.014_bib0011","doi-asserted-by":"crossref","first-page":"542","DOI":"10.15171\/ijhpm.2017.122","article-title":"Misuse of artemisinin combination therapies by clients of medicine retailers suspected to have malaria without prior parasitological confirmation in Nigeria","volume":"7","author":"Nwokolo","year":"2018","journal-title":"Int J Health Policy Manage"},{"key":"10.1016\/j.jgar.2025.07.014_bib0012","series-title":"Stop using antibiotics in healthy animals to prevent the spread of antibiotic resistance. World Health Organization","year":"2017"},{"key":"10.1016\/j.jgar.2025.07.014_bib0013","series-title":"World Health Organization. WHO guidelines on use of medically important antimicrobials in food-producing animals","year":"2017"},{"key":"10.1016\/j.jgar.2025.07.014_bib0014","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1073\/pnas.1503141112","article-title":"Global trends in antimicrobial use in food animals","volume":"112","author":"Van Boeckel","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jgar.2025.07.014_bib0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.07.014_bib0016","doi-asserted-by":"crossref","first-page":"e4444","DOI":"10.1093\/cid\/ciaa859","article-title":"An analysis of antibacterial drug development trends in the United States, 1980-2019","volume":"73","author":"Dheman","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0017","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"Trouiller","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.jgar.2025.07.014_bib0018","series-title":"2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline","year":"2019"},{"key":"10.1016\/j.jgar.2025.07.014_bib0019","series-title":"2021 antibacterial agents in clinical and preclinical development: an overview and analysis","year":"2022"},{"key":"10.1016\/j.jgar.2025.07.014_bib0020","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7665.1","article-title":"Current landscape of antiviral drug discovery","volume":"5","author":"Blair","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.jgar.2025.07.014_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/trstmh\/try146","article-title":"Antimicrobial resistance: learning lessons from antiparasitic, antibacterial and antimycobacterial drug resistance in low-income settings","volume":"113","author":"Whitty","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jgar.2025.07.014_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40249-020-0630-9","article-title":"Neglected tropical diseases: an effective global response to local poverty-related disease priorities","volume":"9","author":"Engels","year":"2020","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.jgar.2025.07.014_bib0023","unstructured":"World Health Organization. R&D funding flows for neglected diseases by disease, year and funding category. World Health Organization https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/r-d-funding-flows-for-neglected-diseases-by-disease-year-and-funding-category\/(accessed March, 2024)."},{"key":"10.1016\/j.jgar.2025.07.014_bib0024","article-title":"Global fund results report reveals COVID-19 devastating impact on HIV, TB and malaria programs","author":"Fund","year":"2021","journal-title":"Glob Fund"},{"key":"10.1016\/j.jgar.2025.07.014_bib0025","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1007\/s00018-016-2299-6","article-title":"Mechanisms of viral mutation","volume":"73","author":"Sanjuan","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000003","article-title":"Why are RNA virus mutation rates so damn high?","volume":"16","author":"Duffy","year":"2018","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0027","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1097\/QAD.0000000000002697","article-title":"Resistance profile of HIV-1 quasispecies in patients under treatment failure using single molecule, real-time sequencing","volume":"34","author":"Monaco","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2025.07.014_bib0028","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2796.2007.01910.x","article-title":"The first postmodern pandemic: 25 years of HIV\/AIDS","volume":"263","author":"Kallings","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.jgar.2025.07.014_bib0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11904-022-00621-1","article-title":"HIV prevention tools across the pregnancy continuum: what works, what does not, and what can we do differently?","volume":"19","author":"Mugambi","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.jgar.2025.07.014_bib0030","series-title":"HIV drug resistance \u2013 brief report 2024","year":"2024"},{"key":"10.1016\/j.jgar.2025.07.014_bib0031","unstructured":"World Health Organization. HIV data and statistics. 2023."},{"key":"10.1016\/j.jgar.2025.07.014_bib0032","series-title":"Joint United Nations Programme on HIV\/AIDS. The urgency of now: AIDS at a crossroads","year":"2024"},{"key":"10.1016\/j.jgar.2025.07.014_bib0033","series-title":"HIV drug resistance [Fact sheet]. World Health Organization","year":"2022"},{"key":"10.1016\/j.jgar.2025.07.014_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.07.014_bib0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/PL00000626","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"57","author":"Sluis-Cremer","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0036","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1021\/ci4002102","article-title":"A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study","volume":"53","author":"Leonis","year":"2013","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.jgar.2025.07.014_bib0037","first-page":"1","article-title":"Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy","volume":"58","author":"Balzarini","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0038","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jgar.2025.07.014_bib0039","series-title":"Conference on Retroviruses and Opportunistic Infections. virtual meeting: Healio","article-title":"In trial, cabotegravir delayed detection of some incident HIV infections","author":"Gallagher","year":"2021"},{"key":"10.1016\/j.jgar.2025.07.014_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1055-3290(97)80003-9","article-title":"Adherence as a particular issue with protease inhibitors","volume":"8","author":"Katzenstein","year":"1997","journal-title":"J Assoc Nurs AIDS Care"},{"key":"10.1016\/j.jgar.2025.07.014_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00224-17","article-title":"Structural insights into HIV reverse transcriptase mutations Q151M and Q151M complex that confer multinucleoside drug resistance","volume":"61","author":"Das","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.014_bib0042","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.43.12.2893","article-title":"Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1","volume":"43","author":"Corbett","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.014_bib0043","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"},{"key":"10.1016\/j.jgar.2025.07.014_bib0044","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2025.07.014_bib0045","first-page":"885","article-title":"A case report of untreatable HIV infection in Harare","volume":"20","author":"Chimbetete","year":"2019","journal-title":"Zimbabwe. South Afr J HIV Med"},{"key":"10.1016\/j.jgar.2025.07.014_bib0046","first-page":"2928","article-title":"Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers","volume":"9","author":"Peterson","year":"2018","journal-title":"Environ Bact Clin Pathogens. Front Microbiol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0047","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.37.8.1563","article-title":"Genetics and mechanisms of glycopeptide resistance in enterococci","volume":"37","author":"Arthur","year":"1993","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.jgar.2025.07.014_bib0048","series-title":"Global Tuberculosis Report 2023","year":"2023"},{"key":"10.1016\/j.jgar.2025.07.014_bib0049","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3181\/00379727-57-14769","article-title":"Effect of streptomycin and other antibiotic substances upon mycobacterium tuberculosis and related organisms","volume":"57","author":"Schatz","year":"1944","journal-title":"Exper Biol Med"},{"key":"10.1016\/j.jgar.2025.07.014_bib0050","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jama.1952.03680120001001","article-title":"Present status of specific drug treatment of tuberculosis","volume":"150","author":"Tempel","year":"1952","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jgar.2025.07.014_bib0051","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0025-6196(25)08548-9","article-title":"Increase in resistance of tubercle bacilli to streptomycin: a preliminary report","volume":"21","author":"Youmans","year":"1946","journal-title":"Proceed Staff Meetings Mayo Clin"},{"key":"10.1016\/j.jgar.2025.07.014_bib0052","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of tuberculosis. A historical perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jgar.2025.07.014_bib0053","first-page":"117","article-title":"Streptomycin, isoniazid, and para-aminosalicylic acid in the treatment of pulmonary tuberculosis","volume":"73","author":"Wier","year":"1956","journal-title":"Am Rev Tubercul Pulmon Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0054","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0090-1229(77)90090-3","article-title":"Transfer factor treatment in a patient with progressive tuberculosis","volume":"8","author":"Rubinstein","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0055","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: A turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0056","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.jgar.2025.07.014_bib0057","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1128\/JB.01062-06","article-title":"Evidence for recombination in mycobacterium tuberculosis","volume":"188","author":"Liu","year":"2006","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0058","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tim.2021.05.001","article-title":"Efflux pumps in mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance","volume":"30","author":"Laws","year":"2022","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0059","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98862-4","article-title":"Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid","volume":"11","author":"G\u00f3mez-Gonz\u00e1lez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2025.07.014_bib0060","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.0907925106","article-title":"Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis","volume":"106","author":"Zaunbrecher","year":"2009","journal-title":"Proceed Natl Acad Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0061","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase\u2014Peroxidase gene and isoniazid resistance of mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jgar.2025.07.014_bib0062","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1021\/bi00026a004","article-title":"Enzymic characterization of the target for isoniazid in mycobacterium tuberculosis","volume":"34","author":"Quemard","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jgar.2025.07.014_bib0063","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant mycobacterium tuberculosis","volume":"50","author":"Hazb\u00f3n","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.014_bib0064","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/jac\/dkt090","article-title":"High-level resistance to isoniazid and ethionamide in multidrug-resistant mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations","volume":"68","author":"Machado","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.014_bib0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0025-7125(16)32984-4","article-title":"Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children","volume":"51","author":"Steiner","year":"1967","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jgar.2025.07.014_bib0066","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2025.07.014_bib0067","article-title":"Drug resistance in eukaryotic microorganisms","volume":"1","author":"Fairlamb","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0068","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1471-4922(02)02289-4","article-title":"How protozoan parasites evade the immune response","volume":"18","author":"Zambrano-Villa","year":"2002","journal-title":"Trends in Parasitol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0069","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/B978-012373960-5.00374-9","article-title":"The history of malaria and its control","author":"Moss","year":"2008","journal-title":"Int Encyclo Pub Health"},{"key":"10.1016\/j.jgar.2025.07.014_bib0070","series-title":"World malaria report 2023","author":"Organization","year":"2023"},{"key":"10.1016\/j.jgar.2025.07.014_bib0071","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2174\/0929867033456710","article-title":"An over four millennium story behind qinghaosu (artemisinin)-a fantastic antimalarial drug from a traditional Chinese herb","volume":"10","author":"Li","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jgar.2025.07.014_bib0072","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-10-144","article-title":"Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria","volume":"10","author":"Achan","year":"2011","journal-title":"Malar J"},{"key":"10.1016\/j.jgar.2025.07.014_bib0073","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0020-7519(96)00152-X","article-title":"Quinoline antimalarials: mechanisms of action and resistance","volume":"27","author":"Foley","year":"1997","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0074","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","article-title":"Molecular mechanisms of drug resistance in plasmodium falciparum malaria","volume":"74","author":"Wicht","year":"2020","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0075","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.3390\/ijms20225748","article-title":"An overview of drug resistance in protozoal diseases","volume":"20","author":"Capela","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0076","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-018-06221-1","article-title":"Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome","volume":"9","author":"Bridgford","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2025.07.014_bib0077","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1126\/science.aax4735","article-title":"A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites","volume":"367","author":"Birnbaum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jgar.2025.07.014_bib0078","article-title":"Artemisinin-based antimalarial drug therapy: molecular pharmacology and evolving resistance","volume":"4","author":"Heller","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0079","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1086\/656476","article-title":"Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure","volume":"202","author":"Teuscher","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1051\/parasite\/2018021","article-title":"Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination","volume":"25","author":"Ouji","year":"2018","journal-title":"Parasite"},{"key":"10.1016\/j.jgar.2025.07.014_bib0081","series-title":"Chapter 1 - History of malaria and its treatment","first-page":"1","author":"Dagen","year":"2020"},{"key":"10.1016\/j.jgar.2025.07.014_bib0082","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12936-024-04851-z","article-title":"Progress towards malaria elimination in the Greater Mekong Subregion: perspectives from the World Health Organization","volume":"23","author":"Manzoni","year":"2024","journal-title":"Malaria J"},{"key":"10.1016\/j.jgar.2025.07.014_bib0083","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: First Global Approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.07.014_bib0084","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/acs.biochem.9b01105","article-title":"Tafenoquine: A step toward malaria elimination","volume":"59","author":"Lu","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.jgar.2025.07.014_bib0085","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10","author":"Camarda","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2025.07.014_bib0086","series-title":"Practical chemotherapy of malaria: report of a WHO scientific group [meeting held in Geneva from 5 to 12 June 1989]","author":"Organization","year":"1990"},{"key":"10.1016\/j.jgar.2025.07.014_bib0087","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/427997","article-title":"In Vivo selection of plasmodium falciparum pfmdr1 86N coding Alleles by Artemether-Lumefantrine (Coartem)","volume":"191","author":"Sisowath","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0088","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4269\/ajtmh.1999.60.936","article-title":"Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant plasmodium falciparum malaria","volume":"60","author":"Van Vugt","year":"1999","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.jgar.2025.07.014_bib0089","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41565-021-00866-8","article-title":"Nanotechnology approaches for global infectious diseases","volume":"16","author":"Kirtane","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-020-01554-w","article-title":"CRISPR-based strategies in infectious disease diagnosis and therapy","volume":"49","author":"Binnie","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2025.07.014_bib0091","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsinfecdis.7b00268","article-title":"Combating intracellular pathogens with repurposed host-targeted drugs","volume":"4","author":"Schor","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.014_bib0092","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2013.03.026","article-title":"The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets","volume":"442","author":"Flynn","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jgar.2025.07.014_bib0093","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14728222.2023.2185511","article-title":"Parasite and host kinases as targets for antimalarials","volume":"27","author":"Ong","year":"2023","journal-title":"Exp Opinion Therapeut Targets"},{"key":"10.1016\/j.jgar.2025.07.014_bib0094","first-page":"3","article-title":"Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria","author":"Schatz","year":"1944","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.jgar.2025.07.014_bib0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/00034983.1945.11685233","article-title":"Studies on synthetic antimalarial drugs; a comparison of the therapeutic actions of 3349 and of mepacrine hydrochloride on acute attacks of benign tertian malaria","volume":"39","author":"Adams","year":"1945","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.jgar.2025.07.014_bib0096","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","article-title":"Artemisinin: discovery from the Chinese herbal garden","volume":"146","author":"Miller","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jgar.2025.07.014_bib0097","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7164\/antibiotics.29.668","article-title":"Naturally-occurring beta-lactamase inhibitors with antibacterial activity","volume":"29","author":"Brown","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2025.07.014_bib0098","first-page":"5","article-title":"Research on a new antibiotic","author":"Brotzu","year":"1948","journal-title":"Pub Cagliari Inst Hygiene"},{"key":"10.1016\/j.jgar.2025.07.014_bib0099","first-page":"606","article-title":"Vancomycin, a new antibiotic. I. Chemical and biologic properties","volume":"3","author":"McCormick","year":"1955","journal-title":"Antibiot Annu"},{"key":"10.1016\/j.jgar.2025.07.014_bib0100","first-page":"1056","article-title":"Lincomycin: a new antibiotic active against staphylococci and other gram-positive cocci: clinical and laboratory studies","volume":"91","author":"MacLeod","year":"1964","journal-title":"Canadian Med Assoc J"},{"key":"10.1016\/j.jgar.2025.07.014_bib0101","first-page":"281","article-title":"Ilotycin, a new antibiotic","volume":"2","author":"McGuire","year":"1952","journal-title":"Antibiot Chemother (Northfield)"},{"key":"10.1016\/j.jgar.2025.07.014_bib0102","first-page":"449","article-title":"Antibacterial action in cultures of penicillium, with special reference to their use in isolation of Bacillus influenzas","volume":"180","author":"Fleming","year":"1929","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0103","first-page":"957","article-title":"Chemotherapy of acute bacterial infections and tuberculosis","volume":"20","author":"Domagk","year":"1951","journal-title":"Med Welt"},{"key":"10.1016\/j.jgar.2025.07.014_bib0104","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1948.tb27262.x","article-title":"Aureomycin; a product of the continuing search for new antibiotics","volume":"51","author":"Duggar","year":"1948","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jgar.2025.07.014_bib0105","first-page":"182","article-title":"A new antibiotic, azomycin","volume":"6","author":"Maeda","year":"1953","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2025.07.014_bib0106","series-title":"New Drugs at FDA: CDER\u2019s New Molecular Entities and New Therapeutic Biological Products","year":"2022"},{"key":"10.1016\/j.jgar.2025.07.014_bib0107","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1038\/s41467-020-17829-7","article-title":"Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention","volume":"11","author":"Adderley","year":"2020","journal-title":"Nat Commun"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:19:03Z","timestamp":1777101543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":107,"alternative-id":["S2213716525001717"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}